Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid core biomarkers and visinin-like protein-1 (VILIP-1) (CROSBI ID 613070)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Šimić, Goran ; Babić, Mirjana ; Bažadona, Danira ; Borovečki, Fran ; Čerimagić, Denis ; Dejanović, Nenad ; Hajnšek, Sanja ; Henigsberg, Neven ; Jazvinšćak-Jembrek, Maja ; Jovanov- Milošević, Nataša et al. Early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid core biomarkers and visinin-like protein-1 (VILIP-1) // The 2014 Alzheimer's disease congress / The 2014 Alzheimer's disease congress (ur.). London : Delhi: Euroscicon Ltd UK, 2014. str. 8-9

Podaci o odgovornosti

Šimić, Goran ; Babić, Mirjana ; Bažadona, Danira ; Borovečki, Fran ; Čerimagić, Denis ; Dejanović, Nenad ; Hajnšek, Sanja ; Henigsberg, Neven ; Jazvinšćak-Jembrek, Maja ; Jovanov- Milošević, Nataša ; Kalanj-Bognar, Svjetlana ; Kiđemet-Piskaš, Spomenka ; Mustapić, Maja ; Mimica, Ninoslav ; Muck-Šeler, Dorotea ; Nedić- Erjavec, Gordana ; Nikolac-Perković, Matea ; Petrović, Ratimir ; Pivac, Nela ; Presečki, Paola ; Radoš, Milan ; Stanić, Gabrijela ; Švob Štrac, Dubravka ; Vogrinc, Željka ; Vukelić, Željka ; Hof, Patrick R.

engleski

Early diagnosis of Alzheimer's disease by combination of cerebrospinal fluid core biomarkers and visinin-like protein-1 (VILIP-1)

Mild cognitive impairment (MCI) is a syndrome characterized by cognitive impairment without dementia, which primarily affects episodic memory. Patients with MCI often have an initial stage of Alzheimer's disease (AD). In this study we compared the effectiveness of 6 CSF biomarkers (Aβ1-42, total tau, p-tau 181, p-tau 199, p-tau 231 and VILIP-1) in differentiation of AD patients from healthy controls (HC). Biomarker levels among AD, MCI, and HC, were compared using the Kruskal- Wallis test (Aβ1- 42: (χ2=10.763 ; df=2 ; p=0.005) ; total tau: (χ2=34.182 ; df=2 ; p<0.001) ; p-tau 181: (χ2=28.329 ; df=2 ; p<0.001) ; p-tau 231: (χ2=28.215 ; df=2 ; p<0.001) ; p-tau 199: (χ2=24.101 ; df=2 ; p<0.001) ; VILIP-1: (χ2=15.588 ; df=2 ; p<0.001)), followed by the Mann-Whitney U test for pairwise comparisons (Aβ1-42: AD vs MCI (U=1032 ; Z=-3.366 ; p=0.001) ; AD vs HC (U=823.5 ; Z=-0.860 ; p=0.390) ; MCI vs HC (U=347.5 ; Z=-1.224 ; p=0.221) ; total tau: AD vs MCI (U=1110 ; Z=-4.786 ; p<0.001) ; AD vs HC (U=428.5 ; Z=-4.336 ; p<0.001) ; MCI vs HC (U=391 ; Z=-1.508 ; p=0.132) ; p-tau 231: AD vs MCI (U=183 ; Z=-3.712 ; p<0.001) ; AD vs HC (U=48 ; Z=-4.816 ; p<0.001) ; MCI vs HC (U=141.5 ; Z=-1.820 ; p=0.069) ; p-tau 181: AD vs MCI (U=878 ; Z=-2.892 ; p=0.004) ; AD vs HC (U=200 ; Z=-4.793 ; p<0.001) ; MCI vs HC (U=152 ; Z=-3.363 ; p=0.001) ; p- tau 199: AD vs MCI (U=197.5 ; Z=-3.861 ; p<0.001) ; AD vs HC (U=69 ; Z=-4.160 ; p<0.001) ; MCI vs HC (U=158.5 ; Z=-0.990 ; p=0.322) ; VILIP-1: AD vs MCI (U=831 ; Z=-3.295 ; p=0.001) ; AD vs HC (U=300.5 ; Z=-2.931 ; p=0.003) ; MCI vs HC (U=279.5 ; Z=-0.467 ; p=0.641). Phospho-tau biomarkers, especially p-tau 199, reached the highest specificity, sensitivity and area under curve (AUC), as revealed by ROC analysis. MCI patients with a high risk of AD development were detected based on cut-off levels for p-tau biomarkers. Five MCI patients (21, 8%) had increased both p-tau 199 and p-tau 181, while 8 MCI patients (34, 8 %) had increased p-tau 199 only. Additionally, 5 MCI patients also had increased both p-tau 199 and p-tau 231. These 5 MCI will be further monitored as they are at risk of AD development. VILIP-1 is not as reliable as phospho-tau biomarkers, but adds to the overall specificity, sensitivity and AUC in differentiating AD from MCI and HC

Visinin-like protein-1; Alzheimer's disease; mild cognitive impairmen

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

8-9.

2014.

objavljeno

Podaci o matičnoj publikaciji

The 2014 Alzheimer's disease congress

The 2014 Alzheimer's disease congress

London : Delhi: Euroscicon Ltd UK

Podaci o skupu

The 2014 Alzheimer's disease congress

poster

23.06.2014-25.06.2014

London, Ujedinjeno Kraljevstvo

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija